Clinical trial

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

NCT05888402

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Toripalimab Normalized identity: toripalimabView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Concurrent chemoradiation therapy and consolidation immunotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-01-20

PhasePHASE2

Conditions

Local Advanced Non-small Cell Lung Cancerunresolved

Interventions

ToripalimabDRUG · verified · RxNorm: toripalimab

Concurrent chemoradiation therapy and consolidation immunotherapyRADIATION

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Shanghai Junshi Bioscience Co., Ltd.collaborator

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05888402 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.